Last updated: July 31, 2026
Fosinopril sodium is a mature, off-patent angiotensin-converting enzyme inhibitor used for hypertension and heart failure. The product has no meaningful originator exclusivity, no active branded development program of commercial significance, and a fragmented generic market. Clinical-trial activity is concentrated in comparative studies, cardiovascular outcomes research, and retrospective analyses rather than new-drug development. Revenue growth is unlikely without a differentiated formulation, combination product, or expansion into an underpenetrated market.
What is the current clinical-trial status of fosinopril sodium?
Fosinopril sodium is not an active pipeline asset in the conventional sense. Its clinical evidence base was established before generic competition and includes trials evaluating hypertension, heart failure, renal outcomes, cardiovascular events, and comparisons with other ACE inhibitors.
ClinicalTrials.gov lists historical studies involving fosinopril or fosinopril sodium, but the molecule is not associated with a significant late-stage registration program or a new FDA approval pathway. Current research activity is more likely to involve:
- Retrospective cardiovascular outcomes analyses
- Comparative effectiveness studies
- Antihypertensive treatment-pattern research
- Studies of ACE inhibitor use in chronic kidney disease
- Combination therapy and polypharmacy analyses
- Pharmacogenomic or real-world evidence studies
Fosinopril is generally not being evaluated as a new molecular entity, biologic, specialty drug, or novel delivery system.
What clinical indications are supported by fosinopril?
The FDA-approved indications are:
- Treatment of hypertension
- Treatment of heart failure as an adjunctive therapy
Fosinopril is a prodrug hydrolyzed to fosinoprilat. Unlike several other ACE inhibitors, fosinopril has dual hepatic and renal elimination, which has supported its historical use in patients with reduced renal function. The FDA label states that dosage adjustment is not generally required solely because of renal impairment, although clinical monitoring remains necessary (U.S. Food and Drug Administration [FDA], 2006).
What safety issues affect fosinopril trials and prescribing?
The class-level safety profile includes:
- Cough
- Hyperkalemia
- Hypotension
- Renal-function deterioration
- Angioedema
- Fetal toxicity during pregnancy
Fosinopril is contraindicated with a history of ACE inhibitor-associated angioedema and with concomitant aliskiren use in patients with diabetes. It should not be used with sacubitril/valsartan within the required washout period because of angioedema risk. Renal function and serum potassium require monitoring in higher-risk patients.
What is the FDA regulatory status of fosinopril sodium?
Fosinopril sodium was originally commercialized in the United States as Monopril by Bristol-Myers Squibb. The product received FDA approval in the early 1990s and subsequently became available from multiple generic manufacturers.
The regulatory profile is now that of an established immediate-release generic:
| Regulatory characteristic |
Fosinopril sodium status |
| Active ingredient |
Fosinopril sodium |
| Drug class |
ACE inhibitor |
| Original branded product |
Monopril |
| Original sponsor |
Bristol-Myers Squibb |
| Dosage form |
Oral tablets |
| Common strengths |
10 mg, 20 mg, 40 mg |
| FDA indications |
Hypertension and heart failure |
| Regulatory pathway for current suppliers |
ANDA generic pathway |
| New chemical entity exclusivity |
Expired |
| Market status |
Generic and multisource |
| Biosimilar pathway |
Not applicable |
The product is listed in FDA drug databases and marketed through abbreviated new drug applications. FDA approval of a generic fosinopril product requires pharmaceutical equivalence and bioequivalence to the reference product, together with applicable chemistry, manufacturing, and controls documentation.
What is the Orange Book status of fosinopril sodium?
Fosinopril sodium has no commercially meaningful remaining Orange Book patent barrier associated with the original Monopril franchise. The core composition and approved-use exclusivity have expired, allowing generic manufacturers to enter the market.
The principal commercial implication is that generic applicants generally do not need to wait for a future compound-patent expiry. Depending on the product and filing date, an applicant may use a Paragraph III certification where listed patents have expired or a Paragraph IV certification where a listed patent is asserted to be invalid, unenforceable, or not infringed.
How many patents cover fosinopril sodium?
No active, commercially significant U.S. patent estate is generally associated with the core fosinopril sodium molecule. The historic originator estate was directed primarily to:
- The active compound
- Pharmaceutical compositions
- Therapeutic use in hypertension
- Therapeutic use in heart failure
- Manufacturing or preparation methods
Those protections have expired. Any remaining patent risk would be more likely to arise from a specific formulation, combination product, manufacturing process, or device rather than from fosinopril sodium itself.
What formulation patents protect fosinopril?
No widely recognized active formulation patent currently creates a major barrier to ordinary immediate-release fosinopril tablets. Standard tablets are subject to generic substitution and are manufactured by multiple suppliers.
A company seeking new exclusivity would need to create a differentiated product, such as:
- Modified-release fosinopril
- A fixed-dose combination
- A pediatric liquid formulation
- A formulation designed for improved adherence
- A drug-device presentation
- A product with a new approved indication
A new formulation would require independent patent claims and FDA approval. A formulation patent would not automatically block ordinary immediate-release generic tablets.
When did fosinopril lose exclusivity?
Fosinopril lost practical U.S. market exclusivity after expiration of the original Monopril patents and the introduction of generic products. Because the molecule was approved more than three decades ago, its five-year new chemical entity exclusivity and any associated early market protections are long expired.
Fosinopril is therefore in the mature generic phase:
| Commercial phase |
Status |
| Originator launch |
Completed |
| Primary patent protection |
Expired |
| FDA generic entry |
Established |
| Brand-generic substitution |
Broadly available |
| Current exclusivity |
None of commercial significance |
| Generic price pressure |
High |
| Specialty-product opportunity |
Limited without reformulation |
What patent litigation affects fosinopril sodium?
There is no major current U.S. patent litigation campaign comparable to litigation surrounding protected cardiovascular products such as Entresto, Jardiance, Eliquis, or newer obesity medicines.
Historical disputes may have involved generic entry, ANDA certifications, manufacturing claims, or market competition around the Monopril franchise. Those disputes do not create a current barrier to ordinary generic fosinopril sodium tablets.
The principal litigation risks for a new entrant would be:
- Patent infringement claims involving a new formulation
- ANDA litigation involving a newly listed method-of-use patent
- Product-liability claims relating to angioedema, fetal toxicity, or renal injury
- Manufacturing and quality disputes
- Antitrust or supply-related claims in a concentrated generic market
Which companies compete in the fosinopril sodium market?
The competitive field consists primarily of generic manufacturers and pharmaceutical distributors. Supplier participation can vary by strength, dosage form, market, and manufacturing economics.
Typical competitive categories include:
- Large generic manufacturers
- Regional generic companies
- Contract manufacturers
- Authorized distributors
- Pharmacy and hospital suppliers
- National private-label programs
The original branded Monopril franchise no longer controls the commercial market. Competition is based on price, supply reliability, FDA compliance, wholesaler access, and formulary status.
How does fosinopril compare with other ACE inhibitors?
| Drug |
Generic status |
Key commercial distinction |
| Fosinopril |
Generic |
Dual hepatic and renal elimination; smaller market |
| Lisinopril |
Generic |
Broad use, low cost, strong prescribing familiarity |
| Enalapril |
Generic |
Established use in hypertension and heart failure |
| Ramipril |
Generic |
Strong cardiovascular-outcomes positioning |
| Perindopril |
Generic in many markets |
Important in selected international markets |
| Benazepril |
Generic |
Commonly used in hypertension and renal disease |
| Captopril |
Generic |
Older agent with shorter dosing interval |
Fosinopril competes against ACE inhibitors with greater prescribing volume and stronger guideline familiarity. Lisinopril and enalapril generally have a larger commercial footprint in the United States. Fosinopril’s pharmacokinetic profile provides a clinical differentiator, but not a strong pricing advantage.
What is the fosinopril sodium market size and revenue outlook?
A reliable standalone global revenue estimate is difficult because fosinopril is sold as a low-priced generic across multiple suppliers and is often grouped with broader ACE inhibitor or antihypertensive categories in commercial datasets.
The market has the following characteristics:
- Low average selling prices
- High generic substitution
- Limited brand premium
- Stable demand from chronic hypertension treatment
- Declining use relative to newer cardiovascular combinations
- Significant substitution by lisinopril, losartan, valsartan, and newer guideline-preferred therapies
- Limited commercial leverage for individual suppliers
The base-case outlook is flat to declining revenue in developed markets. Unit demand may remain stable because hypertension and heart failure prevalence continue to support chronic treatment, but price erosion and therapeutic substitution are likely to reduce market value.
What is the five-year market projection for fosinopril?
A practical scenario framework is more useful than a single market-size estimate:
| Scenario |
Unit demand |
Net pricing |
Five-year value outlook |
| Base case |
Stable to slightly down |
Continued erosion |
Low-single-digit annual decline |
| Upside case |
Modest growth in selected emerging markets |
Stable generic pricing |
Flat to low-single-digit growth |
| Downside case |
Substitution and supplier exits |
Accelerated erosion |
Mid-single-digit annual decline |
The upside case would require increased use in markets where ACE inhibitors remain underpenetrated, a competitively priced fixed-dose combination, or a supply advantage. A conventional immediate-release tablet is unlikely to generate material revenue growth in the United States or Western Europe.
What generic entry risks exist for fosinopril sodium?
Generic-entry risk is already realized rather than prospective. The relevant commercial risks now concern competition among existing suppliers.
Manufacturing and supply risks
Fosinopril sodium is a chemically synthesized small molecule with no biologic manufacturing barrier. The main operational risks are:
- Active pharmaceutical ingredient supply interruptions
- Limited supplier concentration
- FDA inspection findings
- Batch failures
- Packaging and labeling compliance
- Low-margin production decisions
- Wholesaler inventory rationalization
Manufacturing complexity is moderate. The molecule does not require cold-chain logistics, aseptic filling, viral clearance, or cell-culture production. Its supply chain is therefore less technically protected than that of biologics or complex injectables.
Geographic coverage
Fosinopril is available in multiple international markets, but commercial presence differs substantially by country. Market access depends on:
- National reimbursement systems
- Local generic registration
- Reference-pricing rules
- Hospital tendering
- Prescriber preference
- Local manufacturing requirements
- ACE inhibitor treatment guidelines
The strongest growth opportunity is in markets where hypertension diagnosis and treatment are expanding and low-cost oral medicines remain preferred. Mature markets are more likely to experience substitution and price compression.
Are there licensing deals for fosinopril sodium?
No major current licensing transaction is associated with the core fosinopril sodium molecule. The original branded rights were commercialized by Bristol-Myers Squibb, while current supply is handled through generic manufacturers and distributors.
A commercially relevant licensing opportunity would more likely involve:
- A fixed-dose combination
- A modified-release formulation
- Regional commercialization rights
- A private-label supply agreement
- A pediatric or liquid presentation
- A co-formulated heart-failure product
Licensing the unmodified active ingredient alone would have limited strategic value because generic supply is widely available.
How strong is the fosinopril patent estate?
The core patent estate is weak from a current commercial perspective because the original composition and use protections have expired. Fosinopril has low patent strength but relatively low technical risk.
| Patent factor |
Assessment |
| Core molecule protection |
Expired |
| Compound exclusivity |
Expired |
| Immediate-release tablet protection |
Not a meaningful barrier |
| Method-of-use protection |
Historic protections expired |
| Manufacturing patents |
Limited commercial relevance |
| Formulation opportunity |
Possible but narrow |
| Biosimilar protection |
Not applicable |
| Generic launch barrier |
Low |
| Litigation exposure |
Low for standard tablets |
Key Takeaways
- Fosinopril sodium is a mature, multisource generic ACE inhibitor.
- Its approved uses are hypertension and heart failure.
- No major active clinical-development program is associated with the molecule.
- The original Monopril patent and exclusivity position has expired.
- Standard immediate-release tablets face no meaningful current patent barrier.
- Biosimilar risk does not apply because fosinopril sodium is a small-molecule drug.
- Market value is constrained by low generic pricing and competition from lisinopril, enalapril, ARBs, and newer cardiovascular therapies.
- The five-year base-case outlook is stable to declining value.
- Commercial upside would require a differentiated formulation, combination product, or expansion in underpenetrated international markets.
- Manufacturing barriers are modest, with supply reliability and regulatory compliance more important than proprietary technology.
FAQs
Is fosinopril sodium still being developed as a new cardiovascular drug?
No major new-drug development program is associated with fosinopril sodium. Current research is primarily comparative, observational, or outcomes-focused.
Can a company obtain new patents on fosinopril sodium?
Yes, but a new patent would need to claim a novel formulation, combination, manufacturing process, or use. A patent on the old active ingredient would not be available as a new composition-of-matter right.
Is fosinopril preferred over lisinopril for kidney disease?
Fosinopril has hepatic and renal elimination, which may be clinically useful in selected patients. Treatment selection still depends on renal function, potassium, blood pressure, tolerability, comorbidities, and prescribing guidelines.
Does fosinopril have biosimilar competition?
No. Biosimilars apply to biological products. Fosinopril sodium is a chemically synthesized small molecule and competes through generic drug applications.
Could a fixed-dose fosinopril combination obtain market exclusivity?
A novel fixed-dose combination could receive patent protection and, depending on the regulatory basis and clinical evidence, potentially obtain regulatory exclusivity. That protection would apply to the new combination, not to ordinary fosinopril tablets.
References
-
U.S. Food and Drug Administration. (2006). Fosinopril sodium tablets prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. National Library of Medicine. (2024). Fosinopril sodium tablet: DailyMed drug label. DailyMed.
-
ClinicalTrials.gov. (2024). Search results for fosinopril and fosinopril sodium. National Library of Medicine.
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
